<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-760
Date of Submission: 2025-06-06

This report was submitted by a Physician from Snyder, Rivera and Rogers Medical Center concerning patient ANON-PX-6095. The subject is an adult other with a significant medical history including osteoarthritis, anxiety, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Oral route at a dosage of 166mg, initiated on 2025-05-05 for Neuropathic pain and discontinued on 2025-05-23; Atorvastatin (Statin) administered via the Subcutaneous route at a dosage of 192mg, initiated on 2025-05-05 for Hypercholesterolemia and discontinued on 2025-05-23.

On approximately 2025-05-22, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Angioedema. The Anaphylaxis was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed though and advised method. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2025-760
report_date: '2025-06-06'
patient_details:
  patient_id: ANON-PX-6095
  gender: Other
  relevant_history:
  - osteoarthritis
  - anxiety
  - coronary artery disease
suspected_drugs:
- drug_name: Gabapentin
  dosage: 166mg
  route_of_administration: Oral
  start_date: '2025-05-05'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
  end_date: '2025-05-23'
- drug_name: Atorvastatin
  dosage: 192mg
  route_of_administration: Subcutaneous
  start_date: '2025-05-05'
  indication_for_use: Hypercholesterolemia
  drug_class: Statin
  end_date: '2025-05-23'
adverse_reactions:
- symptom_name: Anaphylaxis
  onset_date: '2025-05-22'
  severity: Mild
  outcome: Recovering
  intervention_required: true
  intervention_details: Prescribed though and advised method.
- symptom_name: Angioedema
  onset_date: '2025-05-22'
  severity: Moderate
  outcome: Fatal
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Not applicable
  naranjo_score: 6
reporting_facility: Snyder, Rivera and Rogers Medical Center
reporter_type: Physician
